NeuroSense Therapeutics Ltd. Ordinary Shares (NRSN)

About NRSN

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyot…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

17

Website

www.neurosense-tx.com/

Fundamentals

1-day range

$0.25$0.5

Market cap

$19.00M

P/E (trailing)

—

P/E (forward)

-0.49

EPS (trailing)

$-0.62

Dividend yield

—

Beta

1.56

Avg. volume

254.0K

Forecasts

3 analyst ratings

NeuroSense Therapeutics Ltd. Ordinary Shares Competitors

Chosen by industry and closest market cap.

• NRSN

  NeuroSense Therapeutics Ltd. Ordinary Shares

  $0.4301

  ▼ 2.03%
  Market cap $19.00MP/E —
  $0.25$1.98
• MRKR

  Marker Therapeutics Inc. Common Stock

  $1.37

  ▼ 7.12%
  Market cap $18.67MP/E —
  $0.8099$2.46
• RKTO

  Rocket One Inc. Common Stock

  $0.7021

  ▼ 2.76%
  Market cap $19.75MP/E —
  $0.691501$2.45
• CELU

  Celularity Inc. Class A Common Stock

  $1.57

  ▼ 25.24%
  Market cap $19.77MP/E —
  $0.5601$4
• GRDX

  GridAI Technologies Corp. Common Stock

  $4.05

  ▲ 1.00%
  Market cap $19.91MP/E —
  $1.73$6.93
• DARE

  Dare Bioscience Inc. Common Stock

  $0.7437

  ▲ 0.64%
  Market cap $19.92MP/E —
  $0.73005$3.78
• NCEL

  NewcelX Ltd. Ordinary Shares

  $3.19

  ▼ 6.73%
  Market cap $17.98MP/E —
  $1.83$24.6

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• 12 Health Care Stocks Moving In Tuesday's After-Market Session
  Benzinga · 8/25/2026

• Eisenberg Or · March 26, 2026 · Grant

  200.0K
• Russek-Blum Niva · March 26, 2026 · Grant

  200.0K
• Binder Hagit · March 26, 2026 · Grant

  200.0K